FDA Advisory Opinion In BD Case Upholds 1996 Medtronic v. Lohr Ruling
This article was originally published in The Gray Sheet
Executive Summary
FDA consideration of preemption of requirements preventing BD's Easy A1C glycated hemoglobin home testing service kit from being marketed in certain states must be preceded by the firm's receipt of premarket approval application go-ahead, FDA maintains.
You may also be interested in...
SUPREME COURT MEDTRONIC V. LOHR RULING LEAVES POSSIBILITY OF TORT CLAIM PREEMPTION BY PMA REQUIREMENTS; PREEMPTION FOR 510(K) DEVICES ELIMINATED
The Supreme Court's ruling June 26 in the case of Medtronic v. Lohr includes opinions from five justices that leave open the possibility that premarket approval application requirements could preempt liability claims.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.